Please check your internet connection and try again.
# Ecospirin (Aspirin, Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a non-steroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis. The enteric coating is designed to delay absorption until the drug reaches the small intestine, potentially reducing gastrointestinal irritation.
## Primary Indications
* **Cardiovascular Risk Reduction:** Prevention of myocardial infarction and stroke in patients with established cardiovascular disease or risk factors.
* **Analgesia and Antipyresis:** Mild to moderate pain and fever (though less commonly used for these indications compared to other NSAIDs).
* **Inflammation:** Management of inflammatory conditions (less common for enteric-coated formulations).
## Adult Dosing
* **Cardiovascular Prevention:**
* **Primary Prevention:** 75-150 mg once daily. The decision for primary prevention should be individualized based on risk assessment.
* **Secondary Prevention:** 75-325 mg once daily. Doses up to 325 mg may be used initially following an acute event, followed by a lower maintenance dose.
* **Analgesia/Antipyresis:** 325-650 mg every 4-6 hours as needed, not to exceed 4000 mg per day.
## Pediatric Dosing
Aspirin is generally **contraindicated** in children and adolescents younger than 18 years for conditions associated with viral infections (e.g., influenza, varicella) due to the risk of Reye's syndrome.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose adjustments are not well-established, but reduced doses may be considered.
* **Renal Impairment:** Use with caution. Dose adjustments may be necessary in severe renal impairment.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, or NSAIDs.
* History of asthma, urticaria, or allergic-type reactions precipitated by aspirin or other NSAIDs.
* Children and adolescents with viral infections.
* Active peptic ulcer disease or gastrointestinal bleeding.
* Certain bleeding disorders.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, gastritis, peptic ulceration, GI bleeding.
* **Hemorrhagic:** Increased bleeding time, epistaxis, bruising.
* **Hypersensitivity:** Bronchospasm, rhinitis, urticaria.
* **Renal:** Acute kidney injury, interstitial nephritis.
* **Auditory:** Tinnitus, hearing loss (often dose-related).
* **Reye's Syndrome:** In children and adolescents with viral infections.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Alcohol:** Increased risk of GI irritation and bleeding.
* **Methotrexate:** Aspirin can increase methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Aspirin may decrease the efficacy of uricosuric agents.
* **Antihypertensives:** May decrease the effectiveness of some antihypertensives.
## Monitoring
* **Signs of bleeding:** Monitor for bruising, hematuria, melena, or any signs of active bleeding.
* **Renal function:** Particularly in patients with pre-existing renal disease or those on concomitant nephrotoxic agents.
* **Hepatic function:** Monitor liver enzymes if clinically indicated.
* **Tinnitus/hearing:** May indicate aspirin toxicity.
## Clinical Pearls
* The enteric coating does not eliminate the risk of GI side effects, especially with long-term use or higher doses.
* Crushing or chewing enteric-coated tablets can disrupt the coating and lead to premature release, increasing the risk of GI irritation.
* For acute pain or fever, immediate-release aspirin formulations are generally preferred.
* Discontinue aspirin at least 7 days prior to elective surgery if feasible.
***
*This information is intended for healthcare professionals. Please verify with current prescribing information and local protocols.*
